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Analgesic-induced renal papillary necrosis first
became a significant factor in mortality tables for two
Australian states, Queensland and New South
Wales, about the year 1960 [1, 21, and the earliest
descriptions of the clinical syndrome and renal
pathology in Australasia (i.e., Australia and New
Zealand) appeared during the following two years
[3—5]. Nearly two decades earlier there had been a
sharp increase in the prevalence of chronic gastric
ulcer in young women living in the same two states
[6—91, but the etiological role of analgesic abuse in
that disease was not recognized until the 1960's [10—
151. Analgesic-induced nephropathy and gastric
ulcer are still common in our community, represent-
ing the most serious elements of what has been
termed in Australia "the analgesic syndrome." Their
combined morbidity and mortality place minor anal-
gesics fourth only to alcohol, tobacco, and sedatives
in the table of our most harmful addictive drugs [16,
171.
It is the purpose of this review to describe the
extent and pattern of non-narcotic analgesic abuse in
Australasia and the prevalence of end-stage renal
disease due to papillary necrosis. Preventive mea-
sures which have been introduced or proposed in this
region are also discussed.
Demography of analgesic abuse
Analgesic abuse implies regular consumption,
without the approval of a doctor, of powders or
tablets for the sake of their psychotropic effects or
else for complaints which either are caused by the
analgesics themselves, or are trivial, so that the
amount and type of drug taken are inappropriate [18—
24]. When analgesics have been taken in the knowl-
edge that they are potentially harmful [19, 20, 22, 231
and when there has been deception about the amount
of drug consumed 119, 23, 25] or difficulty in ceasing
the habit [20, 24, 25], it is clear that dependency has
occurred.
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Most Australian surveys of non-narcotic analgesic
consumption have used information obtained by
means of questionnaires which also dealt with other
forms of drug intake and various health indices. As a
result, their findings have related more often to the
current rate of analgesic consumption than to the
type of powder or tablet taken or the duration of, or
reasons for, taking them. This has made it difficult to
distinguish between legitimate heavy usage and drug
dependence. The pattern of analgesic consumption,
however, indicates that more often than not,
instances of regular, daily ingestion over a period of
a year or more have represented abuse.
Some 16% of the adult female, and rather more
than 10% of the adult male population of Queensland
take analgesics every day 119, 20, 22, 23, 26—28]. The
rate of abuse falls, and the female preponderance
disappears as one moves around Australia in a clock-
wise direction through New South Wales [21, 22, 24,
27, 29—331, the Australian Capital Territory [34],
Victoria [22, 35, 36], and Tasmania [37] to Western
Australia, where no more than 3% of the adult popu-
lation of a provincial town were found to take analge-
sics regularly [38] (Fig. 1). No information is availa-
ble from South Australia or the Northern Territory.
In the three most populous states, where surveys
have been conducted both in the capital cities (Syd-
ney, Melbourne, and Brisbane) and in country
towns, no difference was apparent between metro-
politan and rural populations. Analgesic dependence
is clearly less common in Christchurch [21, and prob-
ably elsewhere in New Zealand [391, than in the
eastern Australian states.
The highest prevalence of analgesic abuse in any
survey was that found in the aboriginal population of
an "outback" country town in New South Wales
132]. On the other hand, the habit of taking analgesic
powders appears to be uncommon amongst non-
British immigrant communities [24, 40, 41].
Age-specific rates for regular analgesic consump-
tion have shown a peak prevalence at about 50 years
of age in Queensland and New South Wales [18—21,
30, 31, 39]. In communities where there is less habi-
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Fig. 1. The distribution of(a) regular analgesic consumption and (b) end-stage renal fri i/tire
due to renal papillary necrosis throughout the six Australian states. Beneath the name of each
state is shown separately the percentage of adult females (F) and males (M) who take one or
more analgesic powders or tablets every day, and beneath that, the yearly rate (per million of
total population) of entrance of patients with renal papillary necrosis (RPN) into the mainte-
nance dialysis/transplantation program in each state (data abstracted from the twice-yearly
reports of the Australian Kidney Foundation Maintenance Dialysis Survey covering the period
1971—1976).
tuation to analgesics, however, the prevalence of
daily ingestion has been highest in old age [34, 381
when chronic painful complaints are most common.
The Queensland and New South Wales data could be
explained either by considerable excess mortality
among analgesic addicts during early middle age, or
else by adoption of the analgesic habit in the first
place by young adults, especially women, during or
shortly after the second world war [19]. The evi-
dence for this latter possibility now seems conclu-
sive, particularly in respect of aspirin-induced gastric
ulcer [6—15].
Composition of analgesics taken by habitues.
Two brands, Bex® and Vincent's®, have been taken
by more than two-thirds of analgesic habitues in this
country [19, 21, 24, 27]. These are the only two
Australian proprietary brands which contain caf-
feine, are available as powders, and are retailed
chiefly through outlets other than pharmacies [19].
Both comprised aspirin, phenacetin, and caffeine
(A.P.C.) prior to 1967 when Vincent's replaced
phenacetin with salicylamide. Bex substituted para-
cetamol in 1975. Bex powders each contained twice
as much phenacetin (350 mg), but rather less caffeine
(68 to 75 mg) than Vincent's (85 to 91 mg per pow-
der). Bex has been the more popular in Queensland
[2, 19], whereas Vincent's appears now to have the
greater share of the Sydney (N.S.W.) market [21,
241.
Tablets of aspirin, phenacetin (replaced by parace-
tamol during the last decade), and codeine are the
preparations of choice for about one in ten Austra-
lian [21, 27] and nearly all New Zealand habitues
[42, 431. Single-drug tablets of aspirin or paracetamol
alone are preferred to the compound preparations by
about one quarter of Australians who take analgesics
every day [2, 27, 281, and by a majority of those who
take them less frequently [24, 27] or who live in
communities where heavy analgesic consumption is
relatively uncommon [36].
Causes of analgesic dependence in Australia
Headache has been the reason most often
advanced for regular, daily ingestion of analgesics,
Tasmania
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its frequency being 65% [27] and 42% [211 in two
surveys. In the first, only 6% of habitues admitted to
taking drugs for their psychotropic effect, whereas in
the latter, 31% did so, a discrepancy due probably to
different wording of the relevant questions. The find-
ings illustrate what is familiar to clinical nephrolo-
gists in this part of the world, namely that the first
Bex or Vincent's powder generally is taken on aris-
ing to "clear the head," while further doses are
taken to relieve the dull headache or "let-down"
feeling which follows elimination of the drugs. Caf-
feine-withdrawal headache is documented [44, 45],
and phenacetin may also cause withdrawal symp-
toms [46], or headache [47]. That recurrent head-
ache is often a result, rather than a cause of depen-
dence on analgesics is born out by the observation
that habitues may no longer suffer headaches so
frequently once they overcome their addiction [42].
The third, and only legitimate reason commonly
given for regular analgesic ingestion is arthritis or
other chronic musculoskeletal pain. This accounts
for no more than one fifth of cases in Australia [21,
27].
Like other forms of drug dependence, addiction to
non-narcotic analgesics is more prevalent among
those who give a history of domestic disharmony
[48, 49], neurosis, or other psychiatric disease 120,
22, 32, 49, 501. There is a positive association with
tobacco smoking [20, 48], and possibly with alcohol-
ism [20, 22, 27, 32, 33, 50], but not with the use of
sedatives or tranquillizers [22, 27, 33].
On the other hand, it has been observed in New
South Wales that groups of women who have taken
analgesics, even to the point of endangering their
health, did not appear to be maladjusted mentally or
socially, nor were they less able to be rehabilitated
after renal transplantation than patients with non-
analgesic end-stage renal failure [24, 40]. Psycho-
pathic traits, therefore, can account for but a minori-
ty of cases of analgesic dependency, particularly in
populations where the habit is very common. More-
over, some other explanation must be found for the
demographic pattern of analgesic abuse, particularly
the female preponderance and the striking geograph-
ic distribution. In Queensland and New South
Wales, those principally affected are housewives,
unskilled workers, and the poorly educated [19, 27,
40]; in both sexes, usage increases with worsening
socio-economic status [21, 41, 511, but there is no
evidence either that women who work are more
liable to addiction than those who do not [21, 27, 37,
41], or that marital status is a significant factor [27,
41]. Regular analgesic consumption may start during
the teen-age years [23, 37, 51, 52], but becomes more
widespread during young adult life [19,21,34, 38].
The advertising and sale of analgesics. Fewer
than 10% of Australians obtain their analgesics by
prescription [27, 35, 53], and less than half of all
purchases of these drugs are made from pharmacies
[19, 21]. In this latter respect, there is a notable
difference between tablets of aspirin, 60% of which
are sold by pharmacies, and Bex and Vincent's pow-
ders, of which only 10% are retailed through profes-
sionally supervised outlets. The six Australian states
have yet to place any restriction on the advertise-
ment or sale of non-narcotic analgesics other than a
requirement (not universal) to print on the packet
of phenacetin-containing preparations a warning
against excessive usage. Codeine-containing prepa-
rations may be sold only by pharmacies. In 1967,
federal regulations removed all phenacetin-contain-
ing drugs from the list of analgesics which could be
obtained by prescription through the Australian
National Health Service; in New Zealand, the oppo-
site measure was introduced in 1975, viz, to permit
the supply of phenacetin only on a doctor's
prescription.
The expenditure on advertising of analgesics by
television, radio, and the press throughout Australia
was about $2 million in 1972 (cf, $5.7 million on other
pharmaceuticals, $7.3 million on liquor, and $11.0
million on tobacco, in a total advertising budget of
$204 million [54]). Vincent's also advertise widely on
hoardings, and Bex by means of placards inside and
outside milk bars, general stores and supermarkets.
Widespread advertising and ready availability has
created in many Australian circles a tradition of tak-
ing a powder for any minor complaint, a tradition
which is handed down from mother to daughter [24,
27, 37], but may not yet have become established in
new Australian families whose mother tongue is not
English 124, 40, 41]. On leaving school, young wom-
en are encouraged by their workmates to take pow-
ders to relieve the tedium of the job or to improve
performance [241, and the same remedy is adopted
later to overcome the stress of running a household
with children and the boredom of suburban life. In
these roles, caffeine-containing analgesics are used
by some of our womenfolk much as others might
take strong tea or coffee, or smoke cigarettes.
Analgesic-induced end-stage renal failure
Despite a high level of awareness in the commu-
nity of the dangers of excessive analgesic consump-
tion, and in the face of a generally good response of
established analgesic nephropathy to active medical
and urological therapy [25, 55—57], papillary necro-
sis remains the second most common cause of end-
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stage renal failure in Australia, accounting for some
15 to 20% of patients entering maintenance dialysis
and transplant programs [58—60]. The incidence is
highest in Queensland [61] and New South Wales
[62—64], and lowest in Victoria [65], Tasmania, and
New Zealand [66, 67], conforming to the pattern of
analgesic abuse (Fig. 1).
Post mortem surveys have shown advanced papil-
lary necrosis in 4 to 10% of necropsies in Brisbane
(Queensland) [1, 2, 39], Sydney (New South Wales)
[4, 68] and Melbourne (Victoria) [69] hospitals, but
in less than 1% in Perth (Western Australia) [1] and
Auckland (New Zealand) [1, 70], thus confirming
that analgesic nephropathy is relatively more com-
mon in the eastern Australian states than elsewhere
in Australasia. The higher figures quoted above must
be interpreted with some care, since all came from
hospitals with active renal units. In two hospitals
which established renal failure programs in the late
1960's, Christchurch and the Royal Prince Alfred
Hospital in Sydney, the autopsy incidence of
advanced analgesic nephropathy rose from less than
1% in 1964 [1] to 3—5% in 1971 [2, 68].
The peak age incidence for patients with analgesic
nephropathy starting maintenance dialysis is in the
fifth decade [63]; in autopsy series, advanced papil-
lary necrosis has been found chiefly in the 40 to 80-
year-old age groups [1, 2, 4, 69].
Women comprise some 60 to 85% of end-stage or
terminal renal failure due to analgesics [1, 2, 4, 39,
63, 68, 69], a distinctly higher proportion than might
be expected from the sex ratio of analgesic abuse in
Australia (Fig. 1). Possible explanations are that
women analgesic habitues have, on average, a much
heavier consumption of powders than do men, that
the higher liquid (beer) intake by male habitues is
protective, or that their kidneys are more vulnerable
due to the greater susceptibility of the female urinary
tract to ascending infection.
No estimate is available of the prevalence in this
community of nonterminal renal papillary necrosis,
but in the renal unit populations (in-patient and out-
patient) of two large New South Wales hospitals
(Sydney and Royal Newcastle), analgesic nephropa-
thy is the most common diagnosis, accounting for 25
to 30% of all cases treated (Fig. 2).
Prevention
With an intensive educational program directed at
the public and doctors by the Australian Kidney
Foundation and individual urologists and nephrolo-
gists, official pronouncements on the dangers of non-
narcotic analgesic abuse by the Royal Australasian
College of Physicians [71] and the National Health
and Medical Research Council [72], improved stan-
dards of conservative therapy and replacement of
phenacetin by salicylamide in Vincent's powders
during 1967, one might have expected that the mci-
dences of analgesic-induced end-stage renal failure
would have fallen. There has, however, been no
discernible change in the proportion of cases enter-
ing renal replacement programs between 1967 and
1975 [58, 59, 63], although the number coming to
autopsy has diminished [2]. A factor to be taken into
consideration is that criteria for acceptance on
dialysis have been relaxed since the introduction of
home dialysis programs in 1970—1971, so that
patients in their 50's and early 60's, or those with
extrarenal disease, two categories which include a
high proportion of analgesic nephropathy, are now
more likely to be considered for dialysis therapy. If
phenacetin, not aspirin or paracetamol, were the
major nephrotoxin [25, 73, 74], significant diminu-
tion in the amount of renal papillary necrosis in Aus-
tralia would occur as a result of the recent substitution
of paracetamol for phenacetin in Bex powders.
Nonetheless, it is clear that further preventive
measures are necessary, at least in Queensland and
New South Wales. Perhaps the simplest action
would be to make proprietary analgesics less addic-
tive by removing their psychotrophic ingredients
[52], in particular caffeine [64, 75]. Many medical
commentators have proposed a restriction [71], or
even a prohibition of advertising [20, 64] while con-
fining all sales to pharmacies [25, 52, 71, 74, 76]. It is
conceded, however, that single-drug analgesics
would have to be excluded from these provisions.
Few now advocate making a prescription necessary
for the purchase of analgesics, except perhaps for
phenacetin-, caffeine- or codeine-containing prepara-
tions [5, 35, 43, 56, 76].
So long as identification of individual cases of
analgesic abuse depends upon specific questioning,
the diagnosis will frequently be missed, because of
oversight by the doctor or evasion by the patient.
Screening programs [23, 24], renal clinics [63], and
some gastroenterology clinics [49, 77] now regularly
test their patients' urine for salicylate, using Phenistix
(Ames) or a solution of ferric ions. Far more hitherto
undetected cases would be identified were testing
extended to hypertension and hematology clinics,
and to general practitioners' surgeries. Tests for
phenacetin derivatives are of less general application
since they are laboratory rather than clinical proce-
dures [78].
It is coming to be realised that legislative controls
and medical surveillance alone will not cure this or
any form of drug abuse unless the underlying emo-
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tional, social, domestic or economic causes are iden-
tified and eliminated. Analysis of these problems is
beyond the competence of doctors in clinical prac-
tice, and we must look to the social engineer to
devise a preventive program which combines educa-
tion with correction of the predisposing factors and a
minimum of controls necessary to prevent exploita-
tion of the less intelligent and weaker-willed mem-
bers of the community [32, 51, 52, 74].
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